Argent Capital Management LLC Invests $1.07 Million in Amphastar Pharmaceuticals, Inc. (AMPH)

Argent Capital Management LLC bought a new position in shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) in the second quarter, according to the company in its most recent filing with the SEC. The fund bought 59,850 shares of the company’s stock, valued at approximately $1,069,000. Argent Capital Management LLC owned 0.13% of Amphastar Pharmaceuticals as of its most recent filing with the SEC.

Several other large investors have also recently modified their holdings of the company. Great West Life Assurance Co. Can lifted its position in Amphastar Pharmaceuticals by 13.0% during the 1st quarter. Great West Life Assurance Co. Can now owns 50,874 shares of the company’s stock worth $738,000 after acquiring an additional 5,841 shares in the last quarter. Bank of New York Mellon Corp lifted its position in Amphastar Pharmaceuticals by 11.4% during the 1st quarter. Bank of New York Mellon Corp now owns 519,802 shares of the company’s stock worth $7,536,000 after acquiring an additional 53,214 shares in the last quarter. Comerica Bank lifted its position in Amphastar Pharmaceuticals by 4.1% during the 1st quarter. Comerica Bank now owns 39,612 shares of the company’s stock worth $600,000 after acquiring an additional 1,570 shares in the last quarter. Swiss National Bank lifted its position in Amphastar Pharmaceuticals by 5.3% during the 1st quarter. Swiss National Bank now owns 59,400 shares of the company’s stock worth $861,000 after acquiring an additional 3,000 shares in the last quarter. Finally, UBS Asset Management Americas Inc. lifted its position in Amphastar Pharmaceuticals by 7.6% during the 1st quarter. UBS Asset Management Americas Inc. now owns 149,375 shares of the company’s stock worth $2,166,000 after acquiring an additional 10,600 shares in the last quarter. Institutional investors and hedge funds own 44.26% of the company’s stock.

ILLEGAL ACTIVITY WARNING: This piece of content was reported by The Ledger Gazette and is the property of of The Ledger Gazette. If you are accessing this piece of content on another site, it was illegally stolen and republished in violation of US and international copyright & trademark legislation. The legal version of this piece of content can be viewed at https://ledgergazette.com/2017/10/10/argent-capital-management-llc-invests-1-07-million-in-amphastar-pharmaceuticals-inc-amph.html.

Amphastar Pharmaceuticals, Inc. (NASDAQ AMPH) traded up 0.3749% during trading on Tuesday, reaching $18.7701. The company had a trading volume of 23,595 shares. Amphastar Pharmaceuticals, Inc. has a 12 month low of $12.05 and a 12 month high of $21.75. The company has a market capitalization of $867.08 million, a P/E ratio of 243.7675 and a beta of 1.69. The stock has a 50 day moving average of $16.47 and a 200-day moving average of $16.19.

Amphastar Pharmaceuticals (NASDAQ:AMPH) last issued its quarterly earnings data on Wednesday, August 9th. The company reported $0.11 EPS for the quarter, beating the Zacks’ consensus estimate of $0.06 by $0.05. The business had revenue of $65.20 million for the quarter, compared to analyst estimates of $63.40 million. Amphastar Pharmaceuticals had a return on equity of 2.42% and a net margin of 1.61%. The firm’s revenue for the quarter was down 4.1% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.23 EPS. Equities research analysts expect that Amphastar Pharmaceuticals, Inc. will post $0.27 EPS for the current fiscal year.

Amphastar Pharmaceuticals announced that its board has initiated a share buyback plan on Wednesday, August 9th that allows the company to repurchase $20.00 million in outstanding shares. This repurchase authorization allows the company to reacquire up to 2.8% of its shares through open market purchases. Shares repurchase plans are often a sign that the company’s leadership believes its stock is undervalued.

In other news, Director Floyd F. Petersen sold 39,312 shares of the stock in a transaction dated Wednesday, October 4th. The stock was sold at an average price of $18.59, for a total transaction of $730,810.08. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, Director Richard K. Prins sold 5,000 shares of the stock in a transaction dated Monday, August 14th. The shares were sold at an average price of $14.80, for a total value of $74,000.00. Following the transaction, the director now directly owns 33,844 shares in the company, valued at approximately $500,891.20. The disclosure for this sale can be found here. In the last three months, insiders have sold 126,380 shares of company stock worth $2,268,933. 11.10% of the stock is currently owned by insiders.

Several research firms recently commented on AMPH. Needham & Company LLC boosted their price target on Amphastar Pharmaceuticals from $18.00 to $20.00 and gave the stock a “buy” rating in a research report on Wednesday, September 27th. Piper Jaffray Companies reissued a “buy” rating and set a $19.00 price target on shares of Amphastar Pharmaceuticals in a research report on Sunday, September 17th. ValuEngine lowered Amphastar Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Tuesday, August 22nd. Jefferies Group LLC reissued a “buy” rating and set a $19.00 price target (down from $20.00) on shares of Amphastar Pharmaceuticals in a research report on Friday, August 11th. Finally, BidaskClub lowered Amphastar Pharmaceuticals from a “hold” rating to a “sell” rating

Several other large investors have also recently modified their holdings of the company. Great West Life Assurance Co. Can lifted its position in Amphastar Pharmaceuticals by 13.0% during the 1st quarter. Great West Life Assurance Co. Can now owns 50,874 shares of the company’s stock worth $738,000 after acquiring an additional 5,841 shares in the last quarter. Bank of New York Mellon Corp lifted its position in Amphastar Pharmaceuticals by 11.4% during the 1st quarter. Bank of New York Mellon Corp now owns 519,802 shares of the company’s stock worth $7,536,000 after acquiring an additional 53,214 shares in the last quarter. Comerica Bank lifted its position in Amphastar Pharmaceuticals by 4.1% during the 1st quarter. Comerica Bank now owns 39,612 shares of the company’s stock worth $600,000 after acquiring an additional 1,570 shares in the last quarter. Swiss National Bank lifted its position in Amphastar Pharmaceuticals by 5.3% during the 1st quarter. Swiss National Bank now owns 59,400 shares of the company’s stock worth $861,000 after acquiring an additional 3,000 shares in the last quarter. Finally, UBS Asset Management Americas Inc. lifted its position in Amphastar Pharmaceuticals by 7.6% during the 1st quarter. UBS Asset Management Americas Inc. now owns 149,375 shares of the company’s stock worth $2,166,000 after acquiring an additional 10,600 shares in the last quarter. Institutional investors and hedge funds own 44.26% of the company’s stock.

ILLEGAL ACTIVITY WARNING: This piece of content was reported by The Ledger Gazette and is the property of of The Ledger Gazette. If you are accessing this piece of content on another site, it was illegally stolen and republished in violation of US and international copyright & trademark legislation. The legal version of this piece of content can be viewed at https://ledgergazette.com/2017/10/10/argent-capital-management-llc-invests-1-07-million-in-amphastar-pharmaceuticals-inc-amph.html.

Amphastar Pharmaceuticals, Inc. (NASDAQ AMPH) traded up 0.3749% during trading on Tuesday, reaching $18.7701. The company had a trading volume of 23,595 shares. Amphastar Pharmaceuticals, Inc. has a 12 month low of $12.05 and a 12 month high of $21.75. The company has a market capitalization of $867.08 million, a P/E ratio of 243.7675 and a beta of 1.69. The stock has a 50 day moving average of $16.47 and a 200-day moving average of $16.19.

Amphastar Pharmaceuticals (NASDAQ:AMPH) last issued its quarterly earnings data on Wednesday, August 9th. The company reported $0.11 EPS for the quarter, beating the Zacks’ consensus estimate of $0.06 by $0.05. The business had revenue of $65.20 million for the quarter, compared to analyst estimates of $63.40 million. Amphastar Pharmaceuticals had a return on equity of 2.42% and a net margin of 1.61%. The firm’s revenue for the quarter was down 4.1% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.23 EPS. Equities research analysts expect that Amphastar Pharmaceuticals, Inc. will post $0.27 EPS for the current fiscal year.

Amphastar Pharmaceuticals announced that its board has initiated a share buyback plan on Wednesday, August 9th that allows the company to repurchase $20.00 million in outstanding shares. This repurchase authorization allows the company to reacquire up to 2.8% of its shares through open market purchases. Shares repurchase plans are often a sign that the company’s leadership believes its stock is undervalued.

In other news, Director Floyd F. Petersen sold 39,312 shares of the stock in a transaction dated Wednesday, October 4th. The stock was sold at an average price of $18.59, for a total transaction of $730,810.08. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, Director Richard K. Prins sold 5,000 shares of the stock in a transaction dated Monday, August 14th. The shares were sold at an average price of $14.80, for a total value of $74,000.00. Following the transaction, the director now directly owns 33,844 shares in the company, valued at approximately $500,891.20. The disclosure for this sale can be found here. In the last three months, insiders have sold 126,380 shares of company stock worth $2,268,933. 11.10% of the stock is currently owned by insiders.

Several research firms recently commented on AMPH. Needham & Company LLC boosted their price target on Amphastar Pharmaceuticals from $18.00 to $20.00 and gave the stock a “buy” rating in a research report on Wednesday, September 27th. Piper Jaffray Companies reissued a “buy” rating and set a $19.00 price target on shares of Amphastar Pharmaceuticals in a research report on Sunday, September 17th. ValuEngine lowered Amphastar Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Tuesday, August 22nd. Jefferies Group LLC reissued a “buy” rating and set a $19.00 price target (down from $20.00) on shares of Amphastar Pharmaceuticals in a research report on Friday, August 11th. Finally, BidaskClub lowered Amphastar Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Friday, August 11th. Two investment analysts have rated the stock with a sell rating, one has issued a hold rating and five have issued a buy rating to the stock. The company presently has an average rating of “Hold” and an average price target of $20.17.

Amphastar Pharmaceuticals Profile

Amphastar Pharmaceuticals, Inc is a specialty pharmaceutical company. The Company focuses primarily on developing, manufacturing, marketing and selling generic and injectable, inhalation and intranasal products. The Company has two segments: finished pharmaceutical products and active pharmaceutical ingredients (API) products.

Want to see what other hedge funds are holding AMPH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH).

Institutional Ownership by Quarter for Amphastar Pharmaceuticals (NASDAQ:AMPH)

Receive News & Ratings for Amphastar Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amphastar Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply